FY 27 rare disease policy and programmatic requests pertaining to rare disease therapy development and research.
2026 · 2nd Quarter (Apr 1 - June 30)
EVERYLIFE FOUNDATION FOR RARE DISEASES
Filed by FAEGRE DRINKER BIDDLE & REATH LLP.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 20, 2026
- Income
- $30,000.00
- Expenses
- Not reported
- Registrant
- FAEGRE DRINKER BIDDLE & REATH LLP
- Filing UUID
- 299481a7-79d1-4c72-a99a-45b91d618911
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Policies pertaining to rare disease therapy development; upcoming FDA Prescription Drug User Fee Act (PDUFA) reauthorization.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.